# PRODUCT INFORMATION



COOH

ÓН

# Prostaglandin D<sub>2</sub>-d<sub>4</sub>

Item No. 312010

CAS Registry No.: 211105-29-2

Formal Name: 9α,15S-dihydroxy-11-oxo-prosta-

5Z,13E-dien-1-oic-3,3,4,4-d<sub>4</sub> acid

Synonym: PGD<sub>2</sub>-d<sub>4</sub> MF:  $C_{20}H_{28}D_4O_5$ FW: 356.5

**Chemical Purity:** ≥98% (Prostaglandin D<sub>2</sub>)

Deuterium

Incorporation:  $\geq$ 99% deuterated forms (d<sub>1</sub>-d<sub>4</sub>);  $\leq$ 1% d<sub>0</sub>

Supplied as: A solution in methyl acetate

-20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Prostaglandin D<sub>2</sub>-d<sub>4</sub> (PGD<sub>2</sub>-d<sub>4</sub>) is intended for use as an internal standard for the quantification of PGD<sub>2</sub> by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

 $PGD_{2}$ -d<sub>4</sub> is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of PGD<sub>2</sub>-d<sub>4</sub> in these solvents is approximately 75, 50, and 100 mg/ml, respectively.

### Description

PGD<sub>2</sub> is the major eicosanoid product of mast cells and is released in large quantities during allergic and asthma $\bar{\text{ti}}$ ic anaphylaxis. Mastocytosis patients produce excessive amounts of PGD $_2$ , which causes vasodilation, flushing, hypotension, and syncopal episodes.  $PGD_2$  is also produced in the brain via an alternative pathway involving a soluble, secreted PGD-synthase also known as β-trace.2,3 In the brain, PGD<sub>2</sub> produces normal physiological sleep and lowering of body temperature. Further pharmacological actions include inhibition of platelet aggregation and relaxation of vascular smooth muscle. PGD2 inhibits human ovarian tumor cell proliferation with an IC<sub>50</sub> of 6.8  $\mu$ M.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/09/2023

## **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM